CXCL8 and its cognate receptors in melanoma progression and metastasis

Future Oncology

Volumn 6, Issue 1, 2010, Pages 111-116

  Singh, Seema ^a   Singh, Ajay P ^a   Sharma, Bhawna ^b   Owen, Laurie B ^a   Singh, Rakesh K ^c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CXCL8; CXCR1; CXCR2; Melanoma

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; ESTRADIOL; INTERLEUKIN 8; SCH 479833; SCH 527123; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG RECEPTOR BINDING; HUMAN; IMMUNE RESPONSE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW;

ANIMALS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-8; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SKIN NEOPLASMS;

EID: 75149124550     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.128     Document Type: Review

References (50)

1. Richmond A, Yang J, Su Y: The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 22(2), 175-186 (2009). ■■ Interesting recent review with updates on chemokines receptors in melanoma.
2. Singh S, Sadanandam A, Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 26(3-4), 453-467 (2007). ■ Highlights the roles of chemokines in tumor angiogenesis and metastasis.
3. Vandercappellen J, Van DJ, Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267(2), 226-244 (2008).
4. Richmond A, Lawson DH, Nixon DW, Chawla RK: Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res. 45(12 Pt 1), 6390-6394 (1985).
5. Richmond A, Balentien E, Thomas HG et al.: Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to β-thromboglobulin. EMBO J. 7(7), 2025-2033 (1988).
6. Matsuo Y, Raimondo M, Woodward TA et al.: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer 125(5), 1027-1037 (2009).
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
8. Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature 445(7130), 851-857 (2007).
9. Varney ML, Johansson SL, Singh RK: Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125(2), 209-216 (2006). ■ Highlights the relevance of CXCL8 and its receptors in malignant melanoma.
10. Singh RK, Varney ML, Bucana CD, Johansson SL: Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res. 9(4), 383-387 (1999).
11. Wang JM, Taraboletti G, Matsushima K, Van DJ, Mantovani A: Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem. Biophys. Res. Commun. 169(1), 165-170 (1990).
12. Di Cesare S, Marshall JC, Logan P et al.: Expression and migratory ana lysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF. J. Carcinog. 6, 2 (2007).
13. Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK: CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br. J. Cancer 100(10), 1638-1646 (2009). ■■ Interesting recent study defining the fuctional roles of CXCR1 and CXCR2 in melanoma progression.
14. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54(12), 3242-3247 (1994).
15. Ugurel S, Rappl G, Tilgen W, Reinhold U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19(2), 577-583 (2001).
16. Gebhardt C, Averbeck M, Viertel A et al.: Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp. Dermatol. 16(8), 636-643 (2007).
17. Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL, Singh RK: Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 20(8), 723-731 (2003).
18. Singh S, Varney M, Singh RK: Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69(2), 411-415 (2009). ■■ Important study of CXCR2 knockout mice defining the host regulation of melanoma progression.
19. Salcedo R, Resau JH, Halverson D et al.: Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 14(13), 2055-2064 (2000).
20. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK: Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8(1), 63-71 (2005).
21. Singh S, Sadanandam A, Nannuru KC et al.: Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin. Cancer Res. 15(7), 2380-2386 (2009).
22. Addison CL, Daniel TO, Burdick MD et al.: The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 165(9), 5269-5277 (2000).
23. Strieter RM, Belperio JA, Phillips RJ, Keane MP: CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol. 14(3), 195-200 (2004).
24. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170(6), 3369-3376 (2003).
25. Shono T, Ono M, Izumi H et al.: Involvement of the transcription factor NF-kB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol. 16(8), 4231-4239 (1996).
26. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151(4), 1105-1113 (1997).
27. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12(4), 375-391 (2001).
28. Giorgini S, Trisciuoglio D, Gabellini C et al.: Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol. Cancer Res. 5(8), 761-771 (2007).
29. Mangahas CR, Dela Cruz GV, Friedman-Jimenez G, Jamal S: Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells. J. Invest. Dermatol. 125(2), 307-311 (2005).
30. Inoue K, Slaton JW, Eve BY et al.: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6(5), 2104-2119 (2000).
31. McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 6(4), 149-156 (2000).
32. Van Hinsbergh VW, Koolwijk P: Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 78(2), 203-212 (2008).
33. Martin D, Galisteo R, Gutkind JS: CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF-kB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 284(10), 6038-6042 (2009).
34. Proost P, Loos T, Mortier A et al.: Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 205(9), 2085-2097 (2008).
35. Norgauer J, Metzner B, Schraufstatter I: Expression and growth-promoting function of the IL-8 receptor b in human melanoma cells. J. Immunol. 156(3), 1132-1137 (1996).
36. Singh S, Sadanandam A, Varney ML, Nannuru KC, Singh RK: Small interfering RNA-mediated CXCR1 or CXCR2 knockdown inhibits melanoma tumor growth and invasion. Int. J. Cancer 126(2), 328-336 (2009).
37. Singh RK, Gutman M, Reich R, Bar-Eli M: Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res. 55(16), 3669-3674 (1995).
38. Herlyn D, Iliopoulos D, Jensen PJ et al.: In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res. 50(8), 2296-2302 (1990).
39. Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U: Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 5(3), 179-181 (1995).
40. Hensley C, Spitzler S, McAlpine BE et al.: In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp. Dermatol. 7(6), 335-341 (1998).
41. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM: IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151(5), 2667-2675 (1993).
42. Singh RK, Varney ML: Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res. 58(7), 1532-1537 (1998).
43. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M: Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 9(5), 307-311 (2008). ■ Important study of immunotherapy in melanoma.
44. Melnikova VO, Bar-Eli M: Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/ MUC18 and IL-8. Pigment Cell Res. 19(5), 395-405 (2006).
45. Fujisawa N, Hayashi S, Miller EJ: A synthetic peptide inhibitor for a-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Melanoma Res. 9(2), 105-114 (1999).
46. Kanda N, Watanabe S: 17b-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J. Invest. Dermatol. 117(2), 274-283 (2001).
47. Bertini R, Allegretti M, Bizzarri C et al.: Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA 101(32), 11791-11796 (2004).
48. White JR, Lee JM, Young PR et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273(17), 10095-10098 (1998).
49. Thatcher TH, McHugh NA, Egan RW et al.: Role of CXCR2 in cigarette smoke-induced lung inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 289(2), L322-L328 (2005).
50. Chapman RW, Minnicozzi M, Celly CS et al.: A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 322(2), 486-493 (2007).